Research has demonstrated favorable therapeutic effects of monoclonal antibodies targeting programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) in treating ESCC (12, 13). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.